key: cord-1038789-8g5xptfe authors: Viskin, Sami title: Important Developments in Long QT Syndrome: Not Only for Arrhythmia Specialists date: 2020-12-16 journal: Circulation DOI: 10.1161/circulationaha.120.051434 sha: b6380bb0748f8ed6ea598d38e88749c92fad3e73 doc_id: 1038789 cord_uid: 8g5xptfe nan In this issue of Circulation, Dagradi et al 1 present what could prove to be a new form of LQTS. ECG screening of athletes is mandatory in Italy. This screening led to the identification of 310 athletes who were referred to a specialty center in Milan to rule out LQTS. 1 Of those referred, 111 (35%) were excluded, mainly because their QT was normal. It should come as no surprise that 1 out of 3 athletes referred for suspected LQTS never had it; both underdiagnosis and overdiagnosis of LQTS are rampant. After further evaluation of the remaining 199 athletes with presumed congenital LQTS, 121 (60%) had genetic confirmation of the diagnosis, whereas 78 (40%) were originally considered to have congenital LQTS without genetic confirmation, also referred to as phenotype+/genotype− LQTS. 1 The genotype+/phenotype− group has always intrigued LQTS specialists, who ponder about the "missing gene." In a recent multicenter study involving ≈1800 nonathletes identified as patients with congenital LQTS, 12 11% had no identifiable mutations in any of the disease-causing genes. Patients with genotypenegative long QT had longer QT intervals and a similar clinical course, in terms of life-threatening arrhythmic events, as genotype-positive patients, demonstrating that the absence of genetic confirmation does not make a well-diagnosed case of LQTS any less dangerous. 12 The authors used genome-wide association analysis in all patients with LQTS and ≈10 000 healthy controls and reported fascinating results. Rather than mutations in a single missing gene, patients with phe-notype+/genotype− LQTS had overrepresentation of genetic variants in several different genes. None of these variants (also present in heathy controls) functions as a standalone disease-causing genetic alteration. Yet, when inherited in combination, these genetic variants act as a polygenic risk factor, increasing the likelihood of clinically significant LQTS. The higher the burden of specific genetic variants in association, the higher the risk. 12 Moving back to the athletes with abnormal QT referred to Milan, 1 let us focus on the phenotype+/genotype− long-QT group of athletes. Of 78 patients in this category, 33 athletes (representing 16% of the entire cohort of athletes with long QT) shared characteristics that would be considered unusual for a familial LQTS: they were all asymptomatic and their family history was invariably negative. Furthermore (and this is the novel finding), their abnormal QT normalized after a law-mandated disqualification from sports led to 3 to 6 months of detraining. 1 Last, resumption of intense sport activities in a few of these athletes led again to abnormal QT prolongation. In a way, these observations fulfilled revised Koch postulates of causality for the proposed entity of sports-induced LQTS. Critics will claim that these athletes do not have LQTS at all, noting that athletes, in general, have longer QT intervals than the general population. However, the mean QTc of athletes with this entity (QTc 492 ms) is >99.9th percentile of QTc values of healthy controls 2 and is longer than the 80th percentile of QTc values recorded among patients with congenital LQTS. 2 Thus, their QT interval was very long. In fact, the QTc of athletes with "sports-induced LQTS" was longer than that of athletes with genetically confirmed LQTS in the same study. 1 1 show that the QT of these athletes was not only long, but also had abnormal morphology. This abnormal morphology included T-wave notching similar to that observed when specific I Kr -potassium channels malfunction in the type II congenital form or in drug-induced or bradycardia-induced LQTS. Abnormal T-wave morphology attests to the presence of arrhythmogenic dispersion of ventricular repolarization. 13 These observations suggest that sports-induced QT prolongation, to the degree observed here, is potentially arrhythmogenic. An opposite argument could be that patients with sports-induced LQTS simply have genotype−/pheno-type+ LQTS and that the QT shortening observed during detraining simply reflects a day-to-day variability of their QT duration that was unrelated to deconditioning. After all, the mean difference between the shortest and longest QTc values among patients with congenital LQTS undergoing repeated ECG recordings over many years is also in the 50 ms range. However, patients with sports-induced LQTS had a very low pretest probability of having a genetic disorder because they were all detected by population screening. Nevertheless, we await the report of wider genetic screening of these athletes, including reporting of their polygenic risk score. 12 The authors speculate that sports-induced increased stretch of myocardial cells activates mechano-gated ion channels that lead to action potential prolongation. 1 Alternatively, intense sports could lead to downregulation of repolarizing potassium channels in susceptible athletes. Downregulation of potassium channels is well documented in animal models of bradycardia-induced LQTS. 14 The resulting prolongation of the action potential allows for increased calcium recruitment. This is a desirable effect from the mechanical point of view because it allows for increased myocardial contractility to increase cardiac output when increasing heart rate is not possible, at the expense of a potentially arrhythmogenic QT prolongation. Regardless of its mechanism, sports-induced LQTS should be taken seriously. In the wake of the article by Dagradi 2418 recognized our first case. The patient is a competitive young athlete with QT prolongation detected by ECG screening, which is also mandatory in Israel. The patient has no personal or family history of LQTS and has a negative genetic screening, but she was diagnosed with and treated for LQTS because her QTc ranged from 461 to 473 ms (equivalent of the 97th to 99th percentile for healthy women) and her response to our quickstanding test 15 was positive. She was allowed to continue competing while on β-blocker therapy. However, the COVID-19 epidemic forced her to stop all training for 4 months. After the description from Milan, we reevaluated her for LQTS and realized her QT had partially but significantly shortened (Figure) . The optimal therapy for athletes with sport-induced LQTS remains to be defined. Competitive sports appear to be safe for appropriately treated patients with congenital LQTS, and a similar approach could be adopted here, individualized by the degree of sports-induced QT prolongation, for those wishing to continue competing. Female athlete diagnosed with congenital long QT syndrome because of a QTc in the 99th percentile (A) and a highly abnormal QT-stretching response to our quick-standing test 15 (B) . Note the notched and biphasic T-waves during quick standing in lead V2 and inferolateral leads, respectively (B). At repeated evaluation after 4 months of detraining, there is partial but significant QT normalization at rest (C) and in response to quick standing (D). Exercise training-induced repolarization abnormalities masquerading as congenital long QT syndrome Determination and interpretation of the QT interval Validating QT-interval measurement using the Apple watch ECG to enable remote monitoring during the COVID-19 pandemic Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database Hypogonadism as a reversible cause of torsades de pointes in men Normalization of acquired QT prolongation in humans by intravenous potassium Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current Modernized classification of cardiac antiarrhythmic drugs Mexiletine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome. Circ Arrhythm Electrophysiol Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3 Mexiletine prevents recurrent torsades de pointes in acquired long QT syndrome refractory to conventional measures Transethnic genome-wide association study provides insights in the genetic architecture and heritability of long QT syndrome Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome Ionic mechanisms of acquired QT prolongation and torsades de pointes in rabbits with chronic complete atrioventricular block The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel. None.